Enanta falls after co's RSV treatment fails main goal in mid-stage study

Enanta Pharmaceuticals

29/09/2025 12:09

** Shares of Enanta Pharmaceuticals ENTA.O fall 13.4% to $6.8 premarket

** Co's experimental RSV treatment fails to meet the main goal of shortening the time taken to reduce the severity of some symptoms

** However, the trial meets multiple secondary goals, including faster improvement on a patient‑reported severity measure and quicker time to when the virus was not detectable in the patient

** As of last close, ENTA stock was up 37.3% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))